Arch Biopartners Inc. (ACHFF)
USD 1.1
(-7.56%)
USD 1.1
(-7.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.17 Million CAD | 88.4% |
| 2022 | 621.64 Thousand CAD | -76.7% |
| 2021 | 2.66 Million CAD | 259.94% |
| 2020 | 741.3 Thousand CAD | 30.52% |
| 2019 | 567.98 Thousand CAD | -15.57% |
| 2018 | 672.69 Thousand CAD | 890.16% |
| 2017 | 67.93 Thousand CAD | -70.08% |
| 2016 | 227.03 Thousand CAD | -65.05% |
| 2015 | 649.5 Thousand CAD | 60.06% |
| 2014 | 405.79 Thousand CAD | 1001.91% |
| 2013 | 36.82 Thousand CAD | -60.75% |
| 2012 | 93.81 Thousand CAD | -57.75% |
| 2011 | 222.04 Thousand CAD | -58.52% |
| 2010 | 535.28 Thousand CAD | 33355.19% |
| 2009 | 1600.00 CAD | -99.8% |
| 2008 | 797.32 Thousand CAD | -16.98% |
| 2007 | 960.41 Thousand CAD | 0.74% |
| 2006 | 953.38 Thousand CAD | -17.63% |
| 2005 | 1.15 Million CAD | -15.87% |
| 2004 | 1.37 Million CAD | -16.02% |
| 2003 | 1.63 Million CAD | 2668.41% |
| 2002 | 59.18 Thousand CAD | -16.12% |
| 2001 | 70.55 Thousand CAD | -97.02% |
| 2000 | 2.36 Million CAD | 87.01% |
| 1999 | 1.26 Million CAD | 575.79% |
| 1998 | 187.16 Thousand CAD | -47.71% |
| 1997 | 357.96 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.78 Million CAD | 181.13% |
| 2024 Q3 | 1.53 Million CAD | -13.98% |
| 2024 Q1 | 636.47 Thousand CAD | -45.65% |
| 2023 FY | 1.17 Million CAD | 88.4% |
| 2023 Q4 | 1.17 Million CAD | -17.32% |
| 2023 Q1 | 718.12 Thousand CAD | 15.52% |
| 2023 Q3 | 1.41 Million CAD | -61.65% |
| 2023 Q2 | 3.69 Million CAD | 414.26% |
| 2022 Q1 | 1.51 Million CAD | -43.24% |
| 2022 FY | 621.64 Thousand CAD | -76.7% |
| 2022 Q4 | 621.64 Thousand CAD | -66.36% |
| 2022 Q2 | 2 Million CAD | 32.17% |
| 2022 Q3 | 1.84 Million CAD | -7.69% |
| 2021 Q2 | 361.56 Thousand CAD | -51.28% |
| 2021 Q3 | 2.7 Million CAD | 646.98% |
| 2021 Q4 | 2.66 Million CAD | -1.21% |
| 2021 FY | 2.66 Million CAD | 259.94% |
| 2021 Q1 | 742.1 Thousand CAD | 0.11% |
| 2020 Q3 | 1.8 Million CAD | 178.85% |
| 2020 Q4 | 741.3 Thousand CAD | -58.99% |
| 2020 FY | 741.3 Thousand CAD | 30.52% |
| 2020 Q2 | 648.25 Thousand CAD | 526.24% |
| 2020 Q1 | 103.51 Thousand CAD | -81.77% |
| 2019 Q2 | 156.5 Thousand CAD | -57.7% |
| 2019 Q1 | 369.98 Thousand CAD | -45.0% |
| 2019 Q3 | 962.15 Thousand CAD | 514.77% |
| 2019 Q4 | 567.98 Thousand CAD | -40.97% |
| 2019 FY | 567.98 Thousand CAD | -15.57% |
| 2018 Q3 | 1.38 Million CAD | 0.2% |
| 2018 FY | 672.69 Thousand CAD | 890.16% |
| 2018 Q4 | 672.69 Thousand CAD | -51.49% |
| 2018 Q2 | 1.38 Million CAD | 527.76% |
| 2018 Q1 | 220.47 Thousand CAD | 224.52% |
| 2017 Q4 | 67.93 Thousand CAD | 97.31% |
| 2017 FY | 67.93 Thousand CAD | -70.08% |
| 2017 Q1 | 85.34 Thousand CAD | -62.41% |
| 2017 Q2 | 297.03 Thousand CAD | 248.03% |
| 2017 Q3 | 34.43 Thousand CAD | -88.41% |
| 2016 FY | 227.03 Thousand CAD | -65.05% |
| 2016 Q4 | 227.03 Thousand CAD | -49.28% |
| 2016 Q2 | 299.99 Thousand CAD | -36.67% |
| 2016 Q1 | 473.72 Thousand CAD | -27.06% |
| 2016 Q3 | 447.62 Thousand CAD | 49.21% |
| 2015 Q2 | 904.84 Thousand CAD | 200.93% |
| 2015 Q1 | 300.68 Thousand CAD | -25.9% |
| 2015 Q4 | 649.5 Thousand CAD | -11.76% |
| 2015 FY | 649.5 Thousand CAD | 60.06% |
| 2015 Q3 | 736.08 Thousand CAD | -18.65% |
| 2014 FY | 405.79 Thousand CAD | 1001.91% |
| 2014 Q4 | 405.79 Thousand CAD | 101.63% |
| 2014 Q3 | 201.25 Thousand CAD | -31.7% |
| 2014 Q1 | 38.83 Thousand CAD | 5.44% |
| 2014 Q2 | 294.66 Thousand CAD | 658.85% |
| 2013 Q3 | 11.89 Thousand CAD | -24.59% |
| 2013 Q4 | 36.82 Thousand CAD | 209.67% |
| 2013 Q1 | 36.71 Thousand CAD | -60.87% |
| 2013 Q2 | 15.76 Thousand CAD | -57.05% |
| 2013 FY | 36.82 Thousand CAD | -60.75% |
| 2012 Q4 | 93.81 Thousand CAD | -39.55% |
| 2012 Q1 | 138.1 Thousand CAD | -37.8% |
| 2012 Q2 | 93.13 Thousand CAD | -32.56% |
| 2012 Q3 | 155.19 Thousand CAD | 66.64% |
| 2012 FY | 93.81 Thousand CAD | -57.75% |
| 2011 FY | 222.04 Thousand CAD | -58.52% |
| 2011 Q4 | 222.04 Thousand CAD | -29.24% |
| 2011 Q3 | 313.79 Thousand CAD | -16.13% |
| 2011 Q2 | 374.14 Thousand CAD | -23.14% |
| 2011 Q1 | 486.75 Thousand CAD | -9.07% |
| 2010 Q2 | 97.00 CAD | -93.94% |
| 2010 FY | 535.28 Thousand CAD | 33355.19% |
| 2010 Q1 | 1600.00 CAD | -86.1% |
| 2010 Q3 | 671.37 Thousand CAD | 692039.18% |
| 2010 Q4 | 535.28 Thousand CAD | -20.27% |
| 2009 Q4 | 11.51 Thousand CAD | 1044.14% |
| 2009 FY | 1600.00 CAD | -99.8% |
| 2009 Q1 | 797.32 Thousand CAD | -71.43% |
| 2009 Q2 | 892.1 Thousand CAD | 11.89% |
| 2009 Q3 | 1006.00 CAD | -99.89% |
| 2008 Q4 | 2.79 Million CAD | 82.1% |
| 2008 Q1 | 960.41 Thousand CAD | -23.73% |
| 2008 Q2 | 1.4 Million CAD | 46.49% |
| 2008 FY | 797.32 Thousand CAD | -16.98% |
| 2008 Q3 | 1.53 Million CAD | 8.92% |
| 2007 FY | 960.41 Thousand CAD | 0.74% |
| 2007 Q4 | 1.25 Million CAD | 64.41% |
| 2007 Q3 | 765.92 Thousand CAD | -4.19% |
| 2007 Q2 | 799.43 Thousand CAD | -16.15% |
| 2007 Q1 | 953.38 Thousand CAD | 14.58% |
| 2006 FY | 953.38 Thousand CAD | -17.63% |
| 2006 Q4 | 832.07 Thousand CAD | 6.12% |
| 2006 Q3 | 784.11 Thousand CAD | 14.11% |
| 2006 Q2 | 687.18 Thousand CAD | -40.63% |
| 2006 Q1 | 1.15 Million CAD | 5.4% |
| 2005 Q4 | 1.09 Million CAD | 24.61% |
| 2005 Q2 | 1.06 Million CAD | -22.41% |
| 2005 Q1 | 1.37 Million CAD | -40.29% |
| 2005 FY | 1.15 Million CAD | -15.87% |
| 2005 Q3 | 881.27 Thousand CAD | -17.45% |
| 2004 Q2 | 1.82 Million CAD | 11.24% |
| 2004 Q1 | 1.63 Million CAD | 2320.72% |
| 2004 FY | 1.37 Million CAD | -16.02% |
| 2004 Q4 | 2.3 Million CAD | 0.94% |
| 2004 Q3 | 2.28 Million CAD | 25.25% |
| 2003 Q4 | 67.68 Thousand CAD | -26.1% |
| 2003 FY | 1.63 Million CAD | 2668.41% |
| 2003 Q1 | 59.18 Thousand CAD | -61.06% |
| 2003 Q2 | 64.49 Thousand CAD | 8.98% |
| 2003 Q3 | 91.58 Thousand CAD | 42.0% |
| 2002 Q1 | 70.55 Thousand CAD | 0.0% |
| 2002 Q4 | 151.97 Thousand CAD | -3.23% |
| 2002 FY | 59.18 Thousand CAD | -16.12% |
| 2002 Q3 | 157.05 Thousand CAD | -11.94% |
| 2002 Q2 | 178.36 Thousand CAD | 152.79% |
| 2001 Q2 | 2.3 Million CAD | -2.44% |
| 2001 Q3 | 2.06 Million CAD | -10.32% |
| 2001 FY | 70.55 Thousand CAD | -97.02% |
| 2001 Q1 | 2.36 Million CAD | 0.0% |
| 2000 Q1 | 1.26 Million CAD | 0.0% |
| 2000 FY | 2.36 Million CAD | 87.01% |
| 1999 FY | 1.26 Million CAD | 575.79% |
| 1999 Q1 | 187.16 Thousand CAD | -50.65% |
| 1998 Q3 | 314.73 Thousand CAD | -8.17% |
| 1998 Q2 | 342.73 Thousand CAD | 0.0% |
| 1998 FY | 187.16 Thousand CAD | -47.71% |
| 1998 Q4 | 379.27 Thousand CAD | 20.51% |
| 1997 FY | 357.96 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 96.985% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 83.778% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.907% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 88.903% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.101% |
| Mesoblast Limited | 667.9 Million USD | 99.825% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1518.423% |
| Genus plc | 1.02 Billion USD | 99.886% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 13.78% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -134.685% |
| Marizyme, Inc. | 22.01 Million USD | 94.68% |
| ContraFect Corporation | 20.67 Million USD | 94.336% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -86.79% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -200.019% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -206.448% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 18.216% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 71.752% |
| MultiCell Technologies, Inc. | 126.22 USD | -927781.477% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -24.634% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.089% |
| EV Biologics, Inc. | 431.71 Thousand USD | -171.284% |
| Q BioMed Inc. | 3.51 Million USD | 66.686% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 96.671% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -51.973% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -348.249% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1486.545% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 99.747% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 96.098% |
| Skye Bioscience, Inc. | 11.94 Million USD | 90.192% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 64.649% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 57.355% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 40.191% |
| IMV Inc. | 31.33 Million USD | 96.262% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -70.356% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 55.01% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1032.202% |
| Alpha Cognition Inc. | 2.45 Million USD | 52.239% |
| HST Global, Inc. | 1526.00 USD | -76647.837% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Halberd Corporation | 10.13 Thousand USD | -11460.28% |
| Enzolytics Inc. | 361.7 Million USD | 99.676% |
| Resverlogix Corp. | 8.11 Million USD | 85.568% |
| Affymax, Inc. | 7.44 Million USD | 84.265% |
| SYBLEU INC | 330.46 Thousand USD | -254.398% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 37.633% |
| argenx SE | 4.54 Billion USD | 99.974% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 95.809% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 97.545% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -5041.003% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 86.913% |
| AVAX Technologies, Inc. | 7.37 Million USD | 84.124% |
| Zenith Capital Corp. | 7410.00 USD | -15705.29% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.965% |
| Ember Therapeutics, Inc. | 184.00 USD | -636406.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -263.937% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -348.1% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.738% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 19.165% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | 61.285% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 97.778% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -26.209% |
| BioStem Technologies, Inc. | 14.56 Million USD | 91.956% |
| ONE Bio Corp. | 70.08 Million USD | 98.329% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -1951.305% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -50600.087% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -18.544% |
| Agentix Corp. | 261.39 Thousand USD | -348.052% |
| LadRx Corporation | 2.3 Million USD | 49.253% |
| Cell Source, Inc. | 195.17 Thousand USD | -500.075% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -143.711% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -231.198% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -231.198% |
| NovAccess Global Inc. | 62.24 Thousand USD | -1781.461% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -83.094% |
| Itoco Inc. | 1.4 Million USD | 16.349% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1124.345% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1004.879% |
| Kadimastem Ltd | 2.3 Million USD | 49.17% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1433.871% |
| CytoDyn Inc. | 11.13 Million USD | 89.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -719.162% |
| Mobile Lads Corp. | 52.00 USD | -2252153.846% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -6450.179% |
| Qrons Inc. | 420.00 USD | -278750.476% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -203.829% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -112.123% |
| Rebus Holdings, Inc. | 5000.00 USD | -23323.44% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -186.055% |
| International Stem Cell Corporation | 5.39 Million USD | 78.271% |
| Bioxytran, Inc. | 137.63 Thousand USD | -750.907% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 92.193% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 92.936% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1382.496% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -35.446% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 84.42% |
| Neutra Corp. | 2851.00 USD | -40979.341% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 96.386% |
| PureTech Health plc | 693.97 Million USD | 99.831% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 85.489% |
| IXICO plc | 15.84 Million USD | 92.608% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 85.859% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.867% |
| CSL Limited | 38.02 Billion USD | 99.997% |
| Cellectis S.A. | 333.99 Million USD | 99.649% |